Role of gemcitabine in ovarian cancer treatment

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Lorusso, A ^a   Di Stefano, A ^a   Fanfani, F ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Gemcitabine; Ovarian cancer

Indexed keywords

ALTRETAMINE; ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TREOSULFAN;

ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG POTENTIATION; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LIVER DYSFUNCTION; LUNG FIBROSIS; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; RESPIRATORY FAILURE; THROMBOCYTOPENIA; VOMITING;

EID: 33745626462     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj979     Document Type: Article

References (55)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics 2003. Can Cancer J Clin 2003; 50: 7.
2. Mcgowan L. Patterns of care in carcinoma of the ovary. Cancer 1993; 71: 628.
3. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and Cisplatin compared with Paclitaxel and Cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996; 334: 1.
4. Williams LL. Secondary cytoreduction of ovarian malignancies. In: Markman M, Hoskins WJ (eds). Cancer of the Ovary. New York: Raven Press, 1993: 187
5. Gadducci A, Sartori E, Maggino T et al. Analysis of failures after negative second-look in patents with advanced ovarian cancer: An Italian multicenter study. Gynecoll Oncol 1998; 68: 150.
6. Eisenhauer EA, Vermorken JK, Van Glabbeke M. Predictors of response to subsequent chemotherapy in Platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963.
7. Alberts DS. Treatment of refractory and recurrent ovarian cancer. Seminars in Oncology 1999; 1(S1): 8-14.
8. Harries M, Gore M. Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. The Lancet 2003; 3: 537-45.
9. Ozols RF. The current role of Gemcitabine in ovarian cancer. Semin Oncol 2001; 28(2): 18-24.
10. Mackey JR, Mani RS, Selner M et al. Functional nucleoside transporters are required for Gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58(19): 4349-57.
11. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Schedule dependence of sensitivity to 2′,2′-Diflurodeoxycytidine -(Gemcitabine) in relation to accumulation and retention of its triphophate in solid tumour cell lines and solid tumours. Blochem Pharmacol 1994; 48: 1327-1339.
12. Ruiz van Haperen VWT, Veerman G, Eriksson S et al. Development and molecular characterization of a 21′,2′-Diflurodeoxycytidine-resistant variant of the human ovarian carcinoma cell fine A2780. Cancer Res 1994; 54: 4138-4143.
13. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJM. Interaction between Cisplatin and Gemcitabine in vitro and in vivo. Semin Oncol 1995; 22(4): 72-79.
14. Distefano M, Ferlini C, De Vincenzo R, Gaggini C, Mancuso M, Scambia G. Antagonistic effect of the combination Gemcitabine/Topotecan in ovarian cancer cells. Oncol Res 2001; 12: 335-359.
15. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of Gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533.
16. Silver DS, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube and peritoneum. Am J Clin Oncol 1999; 22: 450-2.
17. Morhan-Ihirig C, Lembersky B, Christopherson W, Tarassoff P. A phase II evaluation of difluorodeoxycytidine (dfdc) in advanced stage refractory ovarian cancer. Proc Am Soc Clin Oncol 1991; 10: Abstr A646.
18. Shapiro JD, Millward MJ, Rischin D et al. Activity of Gemcitabine in patients with advanced ovarian cancer: Responses seen following Platinum and Paclitaxel. Gynecol Oncol 1996; 63: 89-93.
19. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of Gemcitabine in recurrent Platinum and Paclitaxel resistant ovarian cancer. Gynecol Oncol 2003; 88: 266-9.
20. Markman M, Kennedy A, Webster K et al. Phase 2 trial of single-agent Gemcitabine (GEM) in Platinum(PLT/Paclitaxel(PAC) refractory ovarian cancer (ROC). Proc Am Soc Clin Oncol 2001; 20: 204a, Abstr 813.
21. Coenen M, Berteloot P, Amant F, Vangramberen M, Vergote I. Gemcitabine in Platinum-Paclitaxel resistant ovarian carcinoma. Proc Am Soc Clin Oncol 2000; 1603 (Abstract).
22. Friedlander M, Millward MJ, Bell D et al. A phase II study of Gemcitabine in Platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9: 1343-1345.
23. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent Gemcitabine in Platinum/Paclitaxel refractory ovarian cancer. Gynecol Oncol 2003; 90: 593-6.
24. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of Gemcitabine in ovarian cancer. Ann Onc 1999; 10: 853-55.
25. Neijt JP, Kaufman M, Bauknecht T. Gemcitabine in pretreated ovarian cancer. Ann Oncol 1996; 7: Abstr 329P.
26. Kudelka A, Verschraegen C, Creighton E et al. Preliminary report of a phase II study of Gemcitabine in women with Platinum refractory Mullerian carcinomas. Proc Am Soc Clin Oncol 1999; Abstr 1457.
27. Bergman AM, Ruiz van Haperen VWT, Veerman, Kuiper CM, Peters GJ. Synergistic interaction between Cisplatin and Gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-530.
28. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates Gemcitabine-mediated toxicity synergism with Cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6: 773-81.
29. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses Cisplatin resistance: Demonstration of activity in Platinum and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Onool 2003; 88: 17-21.
30. Nagourney RA, Brewer CA, Radecki S et al. Phase II trial of Gemcitabine plus Cisplatin repeating doublet therapy in previously treated, relapsed ovarian cencer patents. Gynecol Oncol 2003; 88: 35-39.
31. Tewari D, Monk DJ, Hunter M et al. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of Platinum resistant ovarian and peritoneal carcinoma. Invest New Drugs 2004; 4: 475-8.
32. Rose PG. Gemcitabine reverses Platinum resistance in platinum resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 2005; 15(S1): 18-22.
33. Boven E., Schipper H, Erkelens CAM, Hatty SA, Pinedo HM. The influence of the schedule and the dose of Gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993; 68: 52-56.
34. Theodossiou C, Cook JA, Fisher J et al. Interaction of Gemcitabine with Paclitaxel and Cisplatin in human tumor cell lines. Int J Oncol 1998; 12: 825-832.
35. Zoli W, Ricotti L, Barzanti F et al. Schedule-dependent interaction of doxorubicin, Paclitaxel and Gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80: 413-16.
36. Jungnelius JU, Ridderheim M, Perren T et al. Optimal sequence leads to improved dose delivery for gemcitabine (G)/paclitaxel (P) combination in recurrent ovarian cancer: A phase I study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 223a. Abstr 890.
37. Garcia AA, O'Meara A, Bahador A et al. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum resistant ovarian cancer. Gynecol Oncol 2004; 93: 493-B.
38. Greggi S, Salerno MG, D'Agostino G et al. Topotecan and Gemcitabine in Platinum/Paclitaxel-resistant ovarian cancer. Oncology 2001; 60(1): 19-23.
39. Sehouli J, Stengel D, Oskay G et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 2002; 13: 1749-55.
40. Sehouli J, Stengel D, Oskay G et al, Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie (NOGGO). Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. Onkologie 2004; 27: 58-64.
41. D'Agostino G, Ludovisi M, Ferrandina G et al. The liposomal doxorubicin (CAE) and Gemcitabine (GEM) combination is active in relapsed ovarian cancer: A phase II study. Br J Cancer 2003; 89(7): 1180-4.
42. D'Agostino G, Ferrandina G, Garganese G et al. Phase I study of Gemcitabine and liposomial doxorubicin in relapsed ovarian cancer. Oncology 2002; 62: 110-114.
43. Ferrandina G, Paris I, Ludovisi M et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. Gynecol Oncol 2005; 98: 267-73.
44. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second line therapy for Platinum-resistant and Platinum sensitive ovarian carcinoma: A Gynecology Oncology Group study. J Clin Oncol 1998; 16: 405-410.
45. Spanu PG, Ferrero AM, Fuso L et al. Gemcitabine and vinorelbine in relapsed epithelial ovarian cancer: A phase II study. Proc Am Soc Clin Oncol 2001; 20: 213a, Abstr 848.
46. Grecu OM, Kurbacher CM, Mallman P et al. Treosulfan and Gemcitabine in heavily pretreated patients with breast and ovarian cancer: Laboratory study and clinical pilot trial of the ISCO Clinical Study Group. Proc Am Soc Clin Oncol 2001; 20: 187b, Abstr 2500.
47. Du Bois A, Luck HJ, Pfisterer J et al. Second-line Carboplatin and Gemcitabine in Platinum sensitive ovarian cancer: A dose finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001; 12(8): 1115-20.
48. Kose F, Sufliarsky J, Beslija S et al. Gemcitabine plus carboplatin in patients whose epithelial ovarian carcinoma relapsed ≥ 6 months after platinum-containing first-line chemotherapy: Preliminary results of a phase II study. 2003; Eur J Cancer 1(5): Abstr. S53.
49. Pfisterer J, Vergote I, Du Bois A et al. Combination therapy with Gemcitabine and Garboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15(S1): 36-41.
50. Krakowski I, Petit T, Kayitalire L et al. Gemcitabine in combination with Cisplatin in advanced ovarian cancer: A phase II study. Proc Am Soc Clin Oncol 1998; 17: 356a, Abstr 1373.
51. Nogué M, Cirera M, Arcusa I et al. Gemcitabine combined with Cisplatin first line: A phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 357a, Abstr 1377.
52. Bauchnecht T, Grieshaberch, Breitbach G-P et al. Gemcitabine in combination with Cisplatin in previously untreated patients >60 years with Figo stage IIC or IV epithelial ovarian cancer: A phase II study: preliminary results. Proc Am Soc Clin Oncol 1998; 17: 356a, Abstr 1376.
53. Hansen SW, Anderson H, Boman K et al. Gemcitabine, Carboplatin, and Paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Glin Oncol 1999; 18: 357a, Abstr 1379.
54. Poole CJ, Jordan SD, Higgins HB et al. A phase I intra & interpatient dose ranging trial of Gemcitabine, Carboplatin, and Paclitaxel (GCP) in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma. Proc Am Soc Clin Oncol 2001; 20: 220a, Abstr 878.
55. Du Bois A, Pfisterer J. Future options for first line therapy of advanced ovarian cancer. Int J Gynecol Cancer 2005; 15(S1): 42-50.